首页> 外文期刊>Journal of the American College of Cardiology >Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
【24h】

Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.

机译:在无症状或轻度症状的左心功能不全患者中通过心脏再同步治疗预防疾病进展:欧洲队列REVERSE(收缩期左心室功能不全的再同步逆转重塑)试验的见解。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The aim of this study was to determine the long-term effects of cardiac resynchronization therapy (CRT) in the European cohort of patients enrolled in the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. BACKGROUND: Previous data suggest that CRT slows disease progression and improves the outcomes of asymptomatic or mildly symptomatic patients with left ventricular (LV) dysfunction and a wide QRS complex. METHODS: We randomly assigned 262 recipients of CRT pacemakers or defibrillators, with QRS > or =120 ms and LV ejection fraction < or =40% to active (CRT ON; n = 180) versus control (CRT OFF; n = 82) treatment, for 24 months. Mean baseline LV ejection fraction was 28.0%. All patients were in sinus rhythm and receiving optimal medical therapy. The primary study end point was the proportion worsened by the heart failure (HF) clinical composite response. The main secondary study end point was left ventricular end-systolic volume index (LVESVi). RESULTS: In the CRT ON group, 19% of patients were worsened versus 34% in the CRT OFF group (p = 0.01). The LVESVi decreased by a mean of 27.5 +/- 31.8 ml/m(2) in the CRT ON group versus 2.7 +/- 25.8 ml/m(2) in the CRT OFF group (p < 0.0001). Time to first HF hospital stay or death (hazard ratio: 0.38; p = 0.003) was significantly delayed by CRT. CONCLUSIONS: After 24 months of CRT, and compared with those of control subjects, clinical outcomes and LV function were improved and LV dimensions were decreased in this patient population in New York Heart Association functional classes I or II. These observations suggest that CRT prevents the progression of disease in patients with asymptomatic or mildly symptomatic LV dysfunction. (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction [REVERSE]; NCT00271154).
机译:目的:本研究的目的是确定心脏再同步治疗(CRT)在参加REVERSE(收缩期左心室功能障碍的再同步逆转重塑)试验的欧洲患者中的长期作用。背景:以前的数据表明,CRT可以减慢疾病进展并改善无症状或轻度症状的左心室(LV)功能障碍和广泛QRS综合征的患者的预后。方法:我们随机分配262名CRT起搏器或除颤器的接受者,QRS>或= 120 ms,左室射血分数<或= 40%,主动治疗(CRT ON; n = 180)vs对照治疗(CRT OFF; n = 82) ,持续24个月。平均基线左室射血分数为28.0%。所有患者均处于窦性心律并接受最佳药物治疗。主要研究终点是因心力衰竭(HF)临床综合反应而恶化的比例。主要的次要研究终点是左室收缩末期容积指数(LVESVi)。结果:在CRT ON组中,有19%的患者恶化,而CRT OFF组中为34%(p = 0.01)。 CRT ON组的LVESVi平均降低27.5 +/- 31.8 ml / m(2),而CRT OFF组的2.7 +/- 25.8 ml / m(2)(p <0.0001)。 CRT显着延迟了首次HF住院或死亡的时间(危险比:0.38; p = 0.003)。结论:在接受CRT治疗24个月后,与对照组相比,纽约心脏协会I级或II级患者的临床结局和左室功能得到改善,左室尺寸减小。这些观察结果表明,CRT可预防无症状或轻度症状性LV功能障碍患者的疾病进展。 (重新同步反映了收缩期左心室功能障碍[REVERSE]的重塑; NCT00271154)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号